IP Library Granted Patent US 11,098,133
Granted Patent B2
US 11,098,133 · App. 16/302,687 · Granted Aug 24, 2021

Methods of making gels and films using curli nanofibers

Inventors: Anna M. Duraj-Thatte (Boston, MA); Noémie-Manuelle Dorval Courchesne (Montréal, CA); Neel Satish Joshi (Somerville, MA)
C07K17/04A61K9/7007A61K49/0073C07K14/245C07K14/4711C08J3/075C08J5/18C12N15/62B82Y30/00C07K2319/41C07K2319/42C07K2319/43C12N5/0018
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,098,133
App. No.
16/302,687
Granted
Aug 24, 2021
Kind
B2
Abstract

Provided are compositions and methods of making hydrogels, aerogels, films and composites directly from a microbial culture or complex mixture using curli nanofibers.

Claims (15)

1. A biologic hydrogel comprising a curli fiber and a surfactant, wherein the hydrogel comprises at least 3% (w/w) curli fiber, wherein the curli fiber comprises a wild-type CsgA or an engineered CsgA fusion protein, and wherein the engineered CsgA fusion protein comprises a CsgA polypeptide fused to an activity polypeptide.

2. The biologic hydrogel of claim 1 , wherein the activity polypeptide is a mucoadhesive polypeptide, a porin, a ribosomal protein or a plastocyanin.

3. The biologic hydrogel of claim 2 , wherein the mucoadhesive polypeptide is selected from the group consisting of: trefoil factor 1 (TFF1), trefoil factor 2 (TFF2), trefoil factor 3 (TFF3), and a microbial anti-inflammatory molecule (MAM) domain.

4. The biologic hydrogel of claim 1 , wherein CsgA fusion protein comprises a linker polypeptide linker sequence adjoining the CsgA polypeptide and the activity polypeptide.

5. The biologic hydrogel of claim 1 , wherein the engineered CsgA fusion protein further comprises a polypeptide tag selected from the group consisting of a poly-histidine tag, a myc tag, a FLAG tag, a hemagglutinin (HA) tag, and a V5 tag.

6. The biologic hydrogel of claim 1 , comprising a cell, wherein the cell is a bacterial cell, a mammalian cell, a protozoan, or a fungus.

7. The biologic hydrogel of claim 6 ,

wherein the cell is a bacterial cell, and wherein the bacterial cell comprises a heterologous nucleic acid, which comprises a heterologous gene encoding the engineered CsgA fusion, or

wherein the bacterial cell comprises a heterologous nucleic acid, which comprises a heterologous gene encoding a polypeptide selected from the group consisting of an extracellular matrix component, a therapeutic polypeptide, a mucoadhesive polypeptide, a cytokine, an enzyme, an antibody, or an antibody mimetic sequence.

8. The biologic hydrogel of claim 1 , wherein the hydrogel comprises a nucleic acid, an extracellular matrix component, a polysaccharide, a metabolite, a metal ion, a nanoparticle, a polypeptide, cellulose, a vitamin, a nutraceutical, or a detectable compound.

9. The biologic hydrogel of claim 1 , wherein the biologic hydrogel is suitable for use in an application selected from the group consisting of: biocatalysis, chemical production, filtration, isolation of molecules from an aqueous solution, water filtration, bioremediation, nanoparticle synthesis, nanowire synthesis, display of optically active materials, surface coating, structural reinforcement of an object, and delivery of a therapeutic agent, or wherein the biologic hydrogel is suitable for use as a therapeutic biomaterial, a biological scaffold, a delivery system for therapeutic agents, a biosensor, a biocatalyst, a coating, and an electronically conductive material.

10. A particle comprising the biologic hydrogel of claim 1 .

11. A pharmaceutical composition comprising the biologic hydrogel of claim 1 , and a pharmaceutically-acceptable excipient.

12. The biologic hydrogel of claim 1 , wherein the hydrogel comprises at least 5% (w/w) curli fiber.

13. The biologic hydrogel of claim 12 , wherein the hydrogel comprises at least 10% (w/w) curli fiber.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2019
From: COURCHESNE, NOÉMIE-MANUELLE DORVAL; JOSHI, NEEL SATISH; DURAJ-THATTE, ANNA M.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 048422/0600 →
Continuity (2)
Provisional Application 62338835 · May 19, 2016
Related Publication 20190127490A1 · May 2, 2019